A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Gilead Sciences
Merrimack Pharmaceuticals
Northwestern University
Merrimack Pharmaceuticals
National Cancer Institute (NCI)
Fox Chase Cancer Center
M.D. Anderson Cancer Center